For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesJune 2015
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions and individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives and other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to with your name, title, address, and telephone number asking to be added to the AACI's distribution list.

To unsubscribe from AACI Update, please send an e-mail to with your name, title, and unsubscribe in the subject line to be removed from AACI's distribution list.

Mailing address:
3708 Fifth Avenue
Medical Arts Building, 503
Pittsburgh, PA 15213


AACI Welcomes its First Canadian Cancer Center
The Association of American Cancer Institutes is pleased to announce its first Canadian member, Princess Margaret Cancer Centre, in Toronto. PM Cancer Centre is a scientific research center and a teaching hospital affiliated with the University of Toronto Faculty of Medicine as part of the University Health Network. It now stands as the largest cancer center in Canada and one of the five largest in the world.

Canadian cancer centers perform robust clinical research, participate in NCI's National Clinical Trials Network, and possess a keen understanding of cancer diagnosis, treatment, and care. The missions of these centers align closely with the mission of AACI and the Canadian centers encounter many of the same challenges that are faced by U.S. cancer centers. more...

Sotomayor to Lead GW Cancer Center
Eduardo M. Sotomayor, MD, will serve as the inaugural director of the GW Cancer Center (GWCC), beginning July 2015. One of his top priorities will be to attain National Cancer Institute designation within the decade. He will also serve as a professor of medicine. Prior to joining the GWCC Dr. Sotomayor served as the scientific director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center. more...

House Energy and Commerce Committee Approves Cures Bill
On April 30, 2014, U.S. House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Energy and Commerce Subcommittee on Oversight and Investigations Ranking Member Diana DeGette (D-CO) introduced the 21st Century Cures Initiative. Just over one year later, on May 21, 2015, the Energy and Commerce Committee unanimously approved H.R. 6, the 21st Century Cures Act, by a vote of 51-0.

The yearlong process allowed the Committee to host a series of roundtables, hearings, and public comment periods, in an effort to hear from scientists, patients, and insurers alike, in order to improve care and expedite innovation. The nonpartisan bill passed out of Committee addressed many of AACI's initial concerns, including diminished federal funding for the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). more...

Advocates Stress Need for Stable, Predictable Increases for NIH/NCI
More than 70 cancer center directors, physicians, researchers, and advocates representing 25 states visited Capitol Hill on May 7 to urge legislators to provide stable, predictable support for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) in Fiscal Year 2016. The event allowed advocates to participate in nearly 150 meetings with members of Congress and their staff, including leadership and key committee staff.

Hill Day was co-hosted by AACI, the American Association for Cancer Research, and the American Society of Clinical Oncology. AACI, AACR, and ASCO advocates requested that Congress provide at least $32 billion for the NIH and $5.32 billion for the NCI in the coming fiscal year in order to restore NIH's lost purchasing power.

The evening before Hill Day, Senators Barbara Mikulski (D-MD) and Richard Burr (R-NC) were recognized for their outstanding leadership in support of cancer research. more...

(Clockwise, from top photo) U.S. Senator Thom Tillis (R-NC), center, with North Carolina Hill Day participants; Dr. Kathleen Goss, University of Chicago Medicine Comprehensive Cancer Center; AACI President Dr. George Weiner; Yale Cancer Center participants (L-R) Drs. Roy Herbst, Howard Hochster, and David Stern; Pooja Mehta (left), office of U.S. Senator Barbara Mikulski (D-MD), with Rhonda Curry, of the Fred Hutchinson Cancer Research Center.

CRI Annual Meeting Registration Continues

A little more than a month remains to register for the 7th Annual AACI Clinical Research Initiative Meeting. The meeting will be held July 8-9, in Chicago, at The Westin O'Hare. New this year, the meeting will begin on Wednesday at 8:00 am, providing two whole days to accommodate an expanded program to address new and complex clinical trials using immunotherapies and targeted therapies to treat patients.

Register now as late registration goes into effect on June 9th. Please direct questions to Janie Hofacker, 412-647-6331. Potential sponsors should contact Kate Burroughs, 412-647-3844 regarding commercial support opportunities. more...

Early Registration Ends on June 8 for the 2015 AACI/CCAF Annual Meeting
Monday, June 8 is the last day to register for the 2015 AACI/CCAF Annual Meeting at the discounted early registration rate. Regular registration will begin on Tuesday, June 9. The meeting will be held in Washington, DC, October 25-27. Information on the meeting, including the program and electronic registration is available on the AACI website. more...
News from the Centers
Awards & Honors
Biggins Selected as a Howard Hughes Medical Institute investigator
Fred Hutchinson Cancer Research Center
Sue Biggins, PhD, a geneticist and biologist at Fred Hutchinson Cancer Research Center who studies the machinery that dividing cells use to ensure their daughter cells receive the correct allotment of chromosomes, has been selected to become a Howard Hughes Medical Institute investigator. She is among 26 of the nation's top biomedical scientists to receive the honor this year out of a pool of nearly 900 applicants. more...
DCI Nurse Named To Serve On ACS Research Grant Team
Duke Cancer Institute
The American Cancer Society recently selected Ellen Parks, RN, OCN, CBCN, to serve as a research stakeholder. As a stakeholder, Parks will be on the Peer Review Committee where she will join scientists, physicians, and cancer experts as they review research grant proposals and help determine those that will make the greatest impact on cancer. more...
Wakelee is Recipient of ECOG-ACRIN Young Investigator Award
Stanford Cancer Institute
Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine. She is also faculty director of the Cancer Clinical Trials Office at the Stanford Cancer Institute. Dr. Wakelee is an active member of the ECOG-ACRIN Thoracic Committee since 2003 and is a contributor to the ECOG-ACRIN Lung Biology Subcommittee and the Thoracic Surgery Subcommittee. more...
Balmain Elected into Royal Society
UCSF Helen Diller Family Comprehensive Cancer Center
Allan Balmain, PhD, FRS, an internationally known expert in cancer genetics, has been elected a Fellow of The Royal Society, the oldest continuously operating scientific society in the world. Dr. Balmain, the Barbara Bass Bakar Distinguished Professor in Cancer Genetics at UCSF, joins the ranks of the most distinguished international scientists drawn from all areas of science, engineering and medicine. Dr. Balmain's selection recognizes his contributions to cancer research, specifically in the realm of cancer genetics and the role of environmental agents on cancer risk. more...
  Theodorescu Named Editor-In-Chief of International Medical Journal
University of Colorado Cancer Center
Dan Theodorescu, MD, director of the University of Colorado Cancer Center and professor of urology and pharmacology at the University of Colorado School of Medicine, has been named an editor-in-chief for an international medical journal that's the first to focus on bladder cancer, one of the most common cancers worldwide. The launch issue of the new journal, Bladder Cancer, is now available online. The multi-disciplinary journal will specialize in all things related to the disease, facilitating new understanding of the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. more...
Foti Recognized by Massachusetts General Hospital Cancer Center
American Association for Cancer Research (AACR)
Margaret Foti, PhD, MD (hc), chief executive officer of the American Association for Cancer Research (AACR), was honored for her "dedication and commitment to solving cancer through research" and for her "passionate advocacy for increased federal funding for cancer research and biomedical science" at Massachusetts General Hospital Cancer Center's eighth annual "one hundred" gala. more...
Dewhirst To Receive Penn Medicine's Yuhas Award
Duke Cancer Institute
Mark Dewhirst, DVM, PhD, Gustavo S. Montana Professor of Radiation Oncology, SoM, and vice director for Basic Sciences, DCI, has been named to receive from the Perelman School of Medicine at the University of Pennsylvania its 2015 John M. Yuhas Award for Excellence in Radiation Oncology. more...
Grants & Gifts
Roswell Park Research Draws More Than $6 Million in Recent Grants
Roswell Park Cancer Institute
Roswell Park Cancer Institute has received $6.19 million in research grant funding, including a five-year, $2.01 million National Cancer Institute (NCI) grant to Xuefang Cao, MD, PhD, Assistant Member in the Department of Immunology. Dr. Cao's work aims to help develop new intervention strategies to improve effectiveness of bone-marrow transplantation, a therapy for treating leukemia, lymphoma and other blood cancers. more...
CPRIT Awards $5.2 Million to CTRC Researchers
Cancer Therapy and Research Center at the University of Texas Health Science Center
Researchers at the Cancer Therapy & Research Center at the UT Health Science Center were awarded more than $5 million in grants that will help them in projects ranging from examining the on/off switch of a cancer-fighting molecule to preventing liver cancer in a majority Hispanic South Texas population. more...
Winship Researchers Get $3.5 Million NCI Award
Winship Cancer Institute
The National Cancer Institute gave two researchers at Emory University's Winship Cancer Center a total of $3.5 million award for their work in informatics technology. David Gutman, MD, PhD, and Lee Cooper, PhD, MS, won the Informatics Technology for Cancer Research U24 award for their work, which is focused on digital microscopy images of tissue slides that have traditionally been used by pathologists for diagnostic purposes. These slides can now be stored as digital images, which produces large databases that can be examined using data analytics. more...
NCI Funding Boosts Breast CT Scanning Research and Development
UC Davis Comprehensive Cancer Center
John M. Boone, MS, PhD, a UC Davis medical physicist and professor of radiology, has been awarded a $2.88 million grant from the National Cancer Institute to further develop and research computed tomography (CT) to detect breast cancer. more...
Leadership Transitions
Cancer Genetic Counselor Helps People to Look Beyond the Numbers
University of New Mexico Cancer Center
Shawnia Ryan, MS, CGC is the second certified cancer genetic counselor in the state of New Mexico and helps people answer their personal cancer genetic questions. She has 16 years of experience in human genetics, including prenatal and pediatric genetics and has practiced in four states: Illinois, California, Washington and New Mexico. She is certified by the American Board of Genetic Counseling and is a member of the National Society of Genetic Counselors. more...
Kachnic to Join Vanderbilt as New Chair of Radiation Oncology
Vanderbilt-Ingram Cancer Center
Lisa Kachnic, MD, professor and chair of Radiation Oncology and associate director of Multidisciplinary Cancer Research at Boston University School of Medicine, and chief of Radiation Oncology at Boston Medical Center, has been named the new professor and chair of the Vanderbilt Department of Radiation Oncology. She will join the faculty on Sept. 21. Dr, Kachnic, who also serves on the Radiation Oncology faculty at Massachusetts General Hospital and is a fellow of the American Society for Therapeutic Radiology and Oncology, succeeds Arnold Malcolm, MD, MBA, who retired from the position in December 2014. more...
Hildebrandt Named Division Chief of Markey Hematology
UK Markey Cancer Center
Gerhard Hildebrandt, MD, has been named the Division Chief of Hematology and Blood and Marrow Transplantation at the University of Kentucky Markey Cancer Center. Dr. Hildebrandt’s clinical focus is cancers of the blood and lymph system. He sees patients before and after blood or marrow stem cell transplantation and treats patients suffering from acute and chronic graft-versus-host disease. He also serves as a professor of medicine in the UK College of Medicine. more...
Research Highlights
Key Receptors Behind Development of Acute Myeloid Leukemia Identified
Simmons Cancer Center, UT Southwestern Medical Center
UT Southwestern Medical Center scientists have discovered that a certain class of receptors that inhibit immune response are crucial for the development of acute myeloid leukemia (AML), the most common acute leukemia affecting adults. "We showed that these receptors are expressed by AML cells and that they support the development of AML. Although counterintuitive, this result is consistent with the generally immune-suppressive and thus tumor-promoting roles of inhibitory receptors in the immune system," said Chengcheng "Alec" Zhang, PhD, a member of the Harold C. Simmons Comprehensive Cancer Center. more...
Molecule Designed to Treat Lung Cancer Shows Promising Results in Mice
Sidney Kimmel Comprehensive Cancer Center
A multidisciplinary team led by Johns Hopkins researcher Venu Raman, PhD, with notable contributions from Guus Bol, Farhad Vesuna and Phuoc Tran of Johns Hopkins, has identified a new therapy for lung cancer, the most common cancer worldwide. The therapy has been in development for six years and involves a first-in-class molecule designed by the team. The molecule, RK-33, interrupts the cell cycle of lung cancer cells without harming normal cells, and it is effective both on its own and in combination with radiation therapy. more...
Study Finds New Potential Melanoma Drug Target
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center researchers have identified a possible new drug target for a potentially deadly form of skin cancer that, when blocked in a pre-clinical study in mice, reduced the cancer's growth. The researchers found high levels of a particular enzyme in melanoma samples that they believe is a driver of the cancer's growth. The enzyme, called interleukin-2 inducible T-cell kinase, or ITK, has not previously been explored as a driver of solid tumors. Normally, it's expressed in a subset of the body's disease-fighting immune cells. more...
Researcher Leads Task Force to Develop Guidelines for Evaluating, Treating Children with Thyroid Cancer
VCU Massey Cancer Center
VCU Massey Cancer Center researcher and Children's Hospital of Richmond at VCU endocrinologist Gary Francis, MD, PhD, recently led a task force commissioned by the American Thyroid Association to develop a set of guidelines for evaluating and treating children with thyroid nodules and cancer. The newly issued guidelines are the first and only set of recommendations aimed at managing patients 18 years of age and younger with thyroid tumors and will provide the best practice standards for diagnosing and treating pediatric thyroid cancer. more...
siRNA-toting Nanoparticles Inhibit Breast Cancer Metastasis
Case Comprehensive Cancer Center, Case Western Reserve University
Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models. The highly aggressive cancer subtype is difficult to manage and, currently, the FDA has no approved targeted treatments. But striking results from a new study make the researchers optimistic they have a potential game-changer for triple negative cancer and more. more...
New Drug Combination Boosts Survival in Advanced Stomach, Esophageal Cancers
Dana-Farber Cancer Institute
Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination. Of the 36 patients in the phase 2 trial, the median overall survival thus far is at least 21 months, reported Peter Enzinger, MD, of Dana-Farber. more...
Researchers Lead Collaborative Charge to Uncover Genetic Diversity of Pancreatic Cancer
Simmons Cancer Center, UT Southwestern Medical Center
A genetic analysis led by UT Southwestern Medical Center researchers suggests that most pancreatic cancers harbor genetic alterations that could be targeted by existing drugs, using their genetic features as a roadmap for treatment. The findings support a precision approach to treating pancreatic cancer. more...
What Makes Cancer Cells Spread? New Device Offers Clues
University of Michigan Comprehensive Cancer Center
Why do some cancer cells break away from a tumor and travel to distant parts of the body? A team of oncologists and engineers from the University of Michigan teamed up to help understand this crucial question. In a paper published in Scientific Reports, researchers describe a new device that is able to sort cells based on their ability to move. The researchers were then able to take the sorted cells that were highly mobile and begin to analyze them on a molecular level. more...
Women With Inherited KRAS-variant Mutation May Be at Increased Breast Cancer Risk Due to Acute Estrogen Withdrawal
Jonsson Comprehensive Cancer Center, UCLA
In a two-year study led by Joanne Weidhaas, MD, PhD, MSM, UCLA researchers have discovered that for women with a relatively common inherited mutation, known as the KRAS-variant, abrupt lowering of estrogen may increase their breast cancer risk and impact breast cancer biology. Scientists also found that women with the KRAS-variant are more likely to develop a second primary breast cancer independent of a first breast cancer. more...
Practice-Changing Study Offers New Option for Tough Breast Cancer Cases
Sidney Kimmel Cancer Center at Thomas Jefferson University
Despite advances in managing and curing some forms of breast cancer, women whose disease becomes metastatic have fewer effective options. A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer. Massimo Cristofanilli, MD, was senior author on the study. more...
Entolimod May be a Promising Treatment Option for Many Solid Tumors
Roswell Park Cancer Institute
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute shared results from the first clinical study of the anticancer effects of the novel agent entolimod. Their findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers. more...
Outsmarting Cancer's Survival Skills
Memorial Sloan Kettering Cancer Center
New research led by investigators at Memorial Sloan Kettering and recently published in the journal Nature gives insight into how melanoma and lung cancer cells that initially respond to targeted therapy develop drug resistance. The study also identifies potential treatment strategies that may delay or prevent tumor relapse in people with these types of cancer. more...
New Combination Treatment Strategy to "Checkmate" Glioblastoma
UC San Diego Moores Cancer Center
Therapies that specifically target mutations in a person's cancer have been much-heralded in recent years, yet cancer cells often find a way around them. To address this, researchers at University of California, San Diego School of Medicine and Moores Cancer Center identified a promising combinatorial approach to treating glioblastomas, the most common form of primary brain cancer. Clark Chen, MD, PhD, was senior author on the study. more...
Molecular Signature Found for Outcomes in Triple Negative Breast Cancer
Huntsman Cancer Institute
Compared to other types of breast cancer, triple negative breast cancers are often more aggressive and have fewer treatment options. In a new study researchers at Huntsman Cancer Institute and the University of Utah have identified a molecular mechanism that triple negative breast cancer cells use to survive and grow. Don Ayer, PhD, was senior author. more...
Scientists Describe Novel Drug Mechanism that Fights Brain Cancer
UC Davis Comprehensive Cancer Center
Researchers at UC Davis have developed and characterized a molecule that interferes with the internal regulation of cancer cells, causing them to self-destruct. This novel mechanism was found to be effective against glioma cells – responsible for a usually fatal type of brain cancer – and could be applicable to other highly aggressive cancers. Nagarekha Pasupuleti was lead author of the study. more...
Investigational Immunotherapy Treatment Shows Durable Response in Metastatic Melanoma
Rutgers Cancer Institute of New Jersey
Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and colleagues, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore. more...
Patients with Gastrointestinal Tumors at Higher Risk of Other Cancers
UC San Diego Moores Cancer Center
Researchers at UC San Diego School of Medicine conducted the first population-based study that characterizes the association and temporal relationship between gastrointestinal stromal tumors (GIST) and other cancers. The results indicate that one in 5.8 patients with GIST will develop additional malignancies before and after their diagnosis. more...
Women with Dense Breasts May Not Need More Screening
UCSF Helen Diller Family Comprehensive Cancer Center
As the debate continues to swirl around the medical significance of dense breasts and whether extra screening should be done, a new study led by UC San Francisco has found that women with dense breasts may need only routine mammograms unless they are at high risk. In their paper, the researchers said that five-year breast cancer risk is a critical component, and breast density should not be the sole factor in deciding whether supplemental screening is justified because not all women with dense breasts are at high risk of cancer. more...
Experimental Drug Discovery Could Eventually Treat Common Blood Cancer
Jonsson Comprehensive Cancer Center, UCLA
UCLA scientists have developed a new drug therapy to treat multiple myeloma, the second most common blood cancer in the United States. This first-of-its-kind experimental treatment would prevent myeloma cells-which accumulate in the bone marrow where they eventually push out healthy blood cells-from growing to slow or stop the spread of the disease. Alan Lichtenstein, MD, a member of UCLA's Jonsson Comprehensive Cancer Center was lead author of the study. more...
Existing Drug May Treat the Deadliest Childhood Brain Tumor, Study Finds
Stanford Cancer Institute
For the first time, scientists have identified an existing drug that slows the growth of the deadliest childhood brain tumor. The drug restricted the tumor's growth in a lab dish and improved the survival time of mice that had the tumor implanted into their brains, according to researchers at the Stanford University School of Medicine, in collaboration with colleagues at other institutions. The work is noteworthy because the disease, a brain stem cancer called diffuse intrinsic pontine glioma, is nearly always fatal and lacks an effective treatment. Michelle Monje, MD, PhD, was senior author of the paper. more...
Urine-Based Test Improves on PSA for Detecting Prostate Cancer
University of Michigan Comprehensive Cancer Center
A new urine-based test improved prostate cancer detection – including detecting more aggressive forms of prostate cancer – compared to traditional models based on prostate serum antigen, or PSA levels, a new study finds. The test, developed at the University of Michigan Comprehensive Cancer Center, is called Mi-Prostate Score, or MiPS. It combines PSA with two markers for prostate cancer, T2:ERG and PCA3, both of which can be detected through a urine sample. The test has been available clinically since September 2013. more...
Failure to Expand ACA Medicaid Coverage Would Widen Breast, Cervical Cancer Screening Disparities in Uninsured and Low-Income Women
VCU Massey Cancer Center
Virginia Commonwealth University Massey Cancer Center researchers recently conducted a study that found low-income and uninsured women in states that are not expanding their Affordable Care Act (ACA) Medicaid coverage are less likely to receive breast and cervical cancer screenings compared to states that are implementing expansions. Lindsay Sabik, PhD, was the study’s lead author. more...
Drugs Stimulate Body's Own Stem Cells to Replace Brain Cells Lost in MS
Case Comprehensive Cancer Center, Case Western Reserve University
A pair of topical medicines already alleviating skin conditions may prove to have another, even more compelling use: instructing stem cells in the brain to reverse damage caused by multiple sclerosis. Led by Paul Tesar, PhD, and colleagues at Case Western Reserve, a multi-institutional team used a new discovery approach to identify drugs that could activate mouse and human brain stem cells in the laboratory. more...
Patient Interest, Willingness to Pay Out of Pocket Costs for Tumor Genetic Profiling Assessed
Fox Chase Cancer Center, Temple Health
Although recent survey participants expressed an interest in comprehensive tumor genetic profiling (CGP)-a novel technology to help identify mutations in pathologically relevant cancer genes for targeted therapy-the participants with lower income, less education, and non-private insurance were less likely to pursue CGP if out-of-pocket costs were involved, according to recent study findings. more...
New Troops in the Fight against Cancer
Rutgers Cancer Institute of New Jersey
Janice M. Mehnert, MD, a leader in the Phase I and Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, is the senior author of research highlighting the latest immunotherapy advances in small cell lung cancer with the drug pembrolizumab. more...
Other News
Online Resource for Precision Cancer Medicine Launched
Dana-Farber Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center has a new website to connect patients and physicians with information about precision cancer medicine, including rich resources on what it is, how it can be applied to cancer care today, and specific clinical trials to address particular genetic mutations. more...
3-D Photography Helps Early Detection in Patients at High Risk for Melanoma
Memorial Sloan Kettering Cancer Center
The creation of three-dimensional avatars is not just a feature of the latest movie blockbuster. It's happening now at Memorial Sloan Kettering - and it's changing the way doctors are monitoring people at increased risk of melanoma, a serious skin cancer that is curable when found early. MSK is the only institution in the world now offering 3-D total-body photography to patients at high risk for the disease due to personal or family history or having multiple abnormal moles. more...
Job Opportunities
Leader, Cancer Prevention Program  
The Robert H. Lurie Comprehensive Cancer Center
Northwestern University


Clinical Research Coordinator  
UC Irvine, Chao Family Comprehensive Cancer Center


Assistant Director of Administrative Programs  
UC Irvine, Chao Family Comprehensive Cancer Center


Director, Clinical Research Protections  
City of Hope


Meeting Announcements

2015 BIG DATA Meeting

2015 BIG DATA Meeting
June 17-18, 2015
The Westin Alexandria, VA
Register here:

7th Annual AACI Clinical Research Initiative Meeting

Register now:
July 8-9, 2015
The Westin O'Hare, Rosemont, IL

2015 Rally for Medical Research Hill Day

Register now:
September 16-17, 2015
Washington, DC

2015 AACI/CCAF Annual Meeting

Register now:
October 25-27, 2015
Mandarin Oriental, Washington, DC